Insys Therapeutics Inc., of Phoenix, submitted an FDA new drug application for it liquid formulation of the cannabinoid dronabinol, a synthetic version of tetrahydrocannabinol intended for the treatment of anorexia associated with weight loss in patients with AIDS and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetics.